Medigene announces management changes

18-Mar-2016 - Germany

MediGene AG announced that the Company's CFO, Peter Llewellyn-Davies, after more than three years of successful management board activity, will leave the Company at his own request by 31st March 2016 to pursue new business challenges.

During his tenure at Medigene Mr. Llewellyn-Davies significantly contributed to the streamlining of the product portfolio and repositioning of the Company towards cancer immunotherapy. Moreover, Peter secured financing for the new corporate strategy through several successful fund raisings with participation of renowned international investors.

Other news from the department people

Most read news

More news from our other portals

Fighting cancer: latest developments and advances